Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction

Trial Profile

Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Umbilical cord mesenchymal stem cell therapy Sclnow Biotechnology (Primary) ; Aspirin
  • Indications Cerebral infarction
  • Focus Adverse reactions
  • Sponsors Sclnow Biotechnology
  • Most Recent Events

    • 16 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top